At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 2, 2026 at 06:30 ET
Alaunos Therapeutics released early non-GLP preclinical data from two diet-induced obesity (DIO) mouse studies showing that its lead drug candidate, ALN1003, produced dose-dependent body weight loss, favorable body composition changes, reduced liver weight, and improved metabolic biomarkers. While the results are encouraging for a non-hormonal obesity treatment, the data are preliminary and subject to limitations, including potential confounding from reduced food and water intake in treated mice.
- ALN1003 showed up to -12.9% mean body weight change vs control (p<0.0001) in DIO mice after 34 days
- Liver weight reduced by up to 55% (high dose group, p<0.01) and liver enzymes (ALT, AST, ALP) improved
- High-dose group had 197 mg/dL glucose vs 320 mg/dL in controls (p<0.0001), and lower total cholesterol
- Drug was generally well tolerated, though mild hypolocomotion and dehydration in high-dose mice were observed
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access